Pregled bibliografske jedinice broj: 1252956
Evaluation of the newly proposed criteria for clinically significant portal hypertension using platelets and transient elastography
Evaluation of the newly proposed criteria for clinically significant portal hypertension using platelets and transient elastography // Journal of hepatology, 75 (2021), Suppl 2
online, 2021. str. S636-S636 doi:10.1016/S0168-8278(21)01843-2 (poster, međunarodna recenzija, sažetak, stručni)
CROSBI ID: 1252956 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Evaluation of the newly proposed criteria for clinically significant portal hypertension using platelets
and transient elastography
(Evaluation of the newly proposed criteria for
clinically significant portal hypertension using
platelets and transient elastography)
Autori
Podrug, Kristian ; Trkulja, Vladimir ; Zelenika, Marko ; Bokun, Tomislav ; Božin, Tonči ; O'Beirne, James ; Grgurević, Ivica
Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, stručni
Izvornik
Journal of hepatology, 75 (2021), Suppl 2
/ - , 2021, S636-S636
Skup
International liver congress (ILC 2021)
Mjesto i datum
Online, 23.06.2021. - 26.06.2021
Vrsta sudjelovanja
Poster
Vrsta recenzije
Međunarodna recenzija
Ključne riječi
portal hypertension ; platelets ; transient elastography
Sažetak
Background and aims: New non-invasive criteria for diagnosing clinically significant portal hypertension (CSPH) have been proposed recently (Pons M. et al. Am Journal Gastroenterol 2020). We aimed to evaluate performance of the proposed criteria in a cohort of patients with compensated chronic liver disease. Methods: We evaluated diagnostic performance of liver stiffness measurement (LSM) by transient elastography and Platelet count (Plt) for CSPH in a cohort of patients with available results of hepatic venous pressure gradient (HVPG) measurements and liver biopsy performed due to suspicion of compensated advanced chronic liver disease (cACLD). Newly proposed non-invasive criteria evaluated here were: LSM≥25 kPa for ruling-in, and Plt≥150 + LSM≤15 kPa for ruling-out CSPH. Only patients >18 years of age, who gave informed consent were included, whereas those with conditions known to affect results of LSM (ALT>5x ULN, liver congestion, extrahepatic biliary obstruction, infiltrative liver neoplasms) were not. Presence of cACLD was confirmed on liver biopsy in patients with bridging fibrosis or cirrhosis. Results: The cohort included 76 patients [78.9% men, median age 62 (34–76) years, 30% obese, mostly suffering from alcoholic (36.8%) or non-alcoholic fatty liver (30.3%) disease], 61 (80.3%) of whom had cACLD, 40 (52.6%) had HVPG ≥10 mmHg (CSPH) and 43 (56.6%) had Plt ≥150. LSM≥25 kPa had 88.9% (95% CI 73.9– 96.9) specificity to rule-in, whereas Plt≥150 + LSM≤15 kPa had 100% (95% CI 73.5–100) sensitivity to rule-out CSPH. By these criteria it was possible to classify correctly 49/76 (64.5%) patients for the presence of CSPH. With increasing BMI, at any given value of Plt, higher LSM was needed for a certain probability of having CSPH. Conclusion: By using these simple new non-invasive criteria almost 65% of patients could be classified correctly for the presence of CSPH. This might facilitate early recognition of CSPH among patients with cACLD and timely introduction of non-selective beta blockers considering the results from PREDESCI trial.
Izvorni jezik
Engleski
Znanstvena područja
Kliničke medicinske znanosti
POVEZANOST RADA
Ustanove:
Medicinski fakultet, Zagreb,
KBC Split,
Klinička bolnica "Dubrava",
Medicinski fakultet, Split
Profili:
Tonči Božin
(autor)
Tomislav Bokun
(autor)
Vladimir Trkulja
(autor)
Ivica Grgurević
(autor)
Citiraj ovu publikaciju:
Časopis indeksira:
- Current Contents Connect (CCC)
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE